296 related articles for article (PubMed ID: 15950012)
1. The neuropsychopharmacology of attention-deficit/hyperactivity disorder.
Pliszka SR
Biol Psychiatry; 2005 Jun; 57(11):1385-90. PubMed ID: 15950012
[TBL] [Abstract][Full Text] [Related]
2. The control of responsiveness in ADHD by catecholamines: evidence for dopaminergic, noradrenergic and interactive roles.
Oades RD; Sadile AG; Sagvolden T; Viggiano D; Zuddas A; Devoto P; Aase H; Johansen EB; Ruocco LA; Russell VA
Dev Sci; 2005 Mar; 8(2):122-31. PubMed ID: 15720370
[TBL] [Abstract][Full Text] [Related]
3. Dopamine-serotonin interactions in attention-deficit hyperactivity disorder (ADHD).
Oades RD
Prog Brain Res; 2008; 172():543-65. PubMed ID: 18772050
[TBL] [Abstract][Full Text] [Related]
4. Effects of methylphenidate on the catecholaminergic system in attention-deficit/hyperactivity disorder.
Wilens TE
J Clin Psychopharmacol; 2008 Jun; 28(3 Suppl 2):S46-53. PubMed ID: 18480677
[TBL] [Abstract][Full Text] [Related]
5. Attention-deficit/hyperactivity disorder and the dopaminergic hypotheses.
Genro JP; Kieling C; Rohde LA; Hutz MH
Expert Rev Neurother; 2010 Apr; 10(4):587-601. PubMed ID: 20367210
[TBL] [Abstract][Full Text] [Related]
6. Catecholamine dysfunction in attention-deficit/hyperactivity disorder: an update.
Prince J
J Clin Psychopharmacol; 2008 Jun; 28(3 Suppl 2):S39-45. PubMed ID: 18480676
[TBL] [Abstract][Full Text] [Related]
7. Animal models concerning the role of dopamine in attention-deficit hyperactivity disorder.
van der Kooij MA; Glennon JC
Neurosci Biobehav Rev; 2007; 31(4):597-618. PubMed ID: 17316796
[TBL] [Abstract][Full Text] [Related]
8. Cerebellar neurotransmission in attention-deficit/hyperactivity disorder: does dopamine neurotransmission occur in the cerebellar vermis?
Glaser PE; Surgener SP; Grondin R; Gash CR; Palmer M; Castellanos FX; Gerhardt GA
J Neurosci Methods; 2006 Feb; 151(1):62-7. PubMed ID: 16451810
[TBL] [Abstract][Full Text] [Related]
9. Catecholamines in attention-deficit hyperactivity disorder: current perspectives.
Pliszka SR; McCracken JT; Maas JW
J Am Acad Child Adolesc Psychiatry; 1996 Mar; 35(3):264-72. PubMed ID: 8714313
[TBL] [Abstract][Full Text] [Related]
10. Imaging the effects of methylphenidate on brain dopamine: new model on its therapeutic actions for attention-deficit/hyperactivity disorder.
Volkow ND; Wang GJ; Fowler JS; Ding YS
Biol Psychiatry; 2005 Jun; 57(11):1410-5. PubMed ID: 15950015
[TBL] [Abstract][Full Text] [Related]
11. Testing computational models of dopamine and noradrenaline dysfunction in attention deficit/hyperactivity disorder.
Frank MJ; Santamaria A; O'Reilly RC; Willcutt E
Neuropsychopharmacology; 2007 Jul; 32(7):1583-99. PubMed ID: 17164816
[TBL] [Abstract][Full Text] [Related]
12. Central nicotinic cholinergic systems: a role in the cognitive dysfunction in attention-deficit/hyperactivity disorder?
Potter AS; Newhouse PA; Bucci DJ
Behav Brain Res; 2006 Dec; 175(2):201-11. PubMed ID: 17081628
[TBL] [Abstract][Full Text] [Related]
13. Fundamentals of attention-deficit/hyperactivity disorder: circuits and pathways.
Arnsten AF
J Clin Psychiatry; 2006; 67 Suppl 8():7-12. PubMed ID: 16961424
[TBL] [Abstract][Full Text] [Related]
14. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder.
Bymaster FP; Katner JS; Nelson DL; Hemrick-Luecke SK; Threlkeld PG; Heiligenstein JH; Morin SM; Gehlert DR; Perry KW
Neuropsychopharmacology; 2002 Nov; 27(5):699-711. PubMed ID: 12431845
[TBL] [Abstract][Full Text] [Related]
15. [Structural and functional neuroanatomy of attention-deficit hyperactivity disorder (ADHD)].
Emond V; Joyal C; Poissant H
Encephale; 2009 Apr; 35(2):107-14. PubMed ID: 19393378
[TBL] [Abstract][Full Text] [Related]
16. Attention-deficit-hyperactivity disorder: an update.
Dopheide JA; Pliszka SR
Pharmacotherapy; 2009 Jun; 29(6):656-79. PubMed ID: 19476419
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological characterization of the norepinephrine and dopamine reuptake inhibitor EB-1020: implications for treatment of attention-deficit hyperactivity disorder.
Bymaster FP; Golembiowska K; Kowalska M; Choi YK; Tarazi FI
Synapse; 2012 Jun; 66(6):522-32. PubMed ID: 22298359
[TBL] [Abstract][Full Text] [Related]
18. Neuropsychologic theory and findings in attention-deficit/hyperactivity disorder: the state of the field and salient challenges for the coming decade.
Nigg JT
Biol Psychiatry; 2005 Jun; 57(11):1424-35. PubMed ID: 15950017
[TBL] [Abstract][Full Text] [Related]
19. Involvement of norepinephrine in the control of activity and attentive processes in animal models of attention deficit hyperactivity disorder.
Viggiano D; Ruocco LA; Arcieri S; Sadile AG
Neural Plast; 2004; 11(1-2):133-49. PubMed ID: 15303310
[TBL] [Abstract][Full Text] [Related]
20. Dopaminergic dysfunction in attention deficit hyperactivity disorder (ADHD), differences between pharmacologically treated and never treated young adults: a 3,4-dihdroxy-6-[18F]fluorophenyl-l-alanine PET study.
Ludolph AG; Kassubek J; Schmeck K; Glaser C; Wunderlich A; Buck AK; Reske SN; Fegert JM; Mottaghy FM
Neuroimage; 2008 Jul; 41(3):718-27. PubMed ID: 18424180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
